Procedures treating peripheral artery disease to grow more than 70% by 2012

January 21, 2008, Waltham, MA--According to a new research report from Millennium Research Group, minimally invasive procedures treating peripheral artery disease (PAD) will grow more than 70% by 2012, driven largely by the availability of successful treatment options including laser atherectomy and thrombectomy.

Jan 21st, 2008

January 21, 2008, Waltham, MA--According to a new research report from Millennium Research Group, "US Markets for Plaque and Thrombus Management Devices 2008," minimally invasive procedures treating peripheral artery disease (PAD) will grow more than 70% by 2012, driven largely by the availability of successful treatment options including laser atherectomy and thrombectomy.

Today, only a small subset of patients actually receives an interventional treatment. Often times, PAD patients are treated with bypass surgery or worse, are forced to have limbs amputated because PAD is not caught in time. Less invasive procedures, such as atherectomy and thrombectomy, which remove plaque and thrombus matter that has formed along the vessel wall, are available if the disease is diagnosed before the critical end stage of its lifecycle.

Physician awareness of minimally invasive plaque and thrombus management procedures is expanding primarily due to research and clinical trials on a number of innovative devices. As a result, more physicians will adopt these new technologies, thus driving procedure growth and improving patient care.

"Today, physicians have more options for treating patients with PAD," says Bina Mistry, analyst at Millennium Research Group. "Specifically, we are noticing a large increase in the number of individuals receiving laser atherectomy and mechanical thrombectomy--two types of plaque and thrombus removal procedures--both in the US and in Europe."

The "Plaque and Thrombus Management Devices 2008" series includes coverage in the US and Europe for atherectomy, thrombectomy, chronic total occlusion crossing devices, and embolic protection devices. Coverage of industry competitors includes FoxHollow Technologies (ev3), Boston Scientific, Possis Medical, Spectranetics, and many others.

More in Home